相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Developing interactions with industry in rare diseases: lessonslearned and continuing challenges
Susan A. Berry et al.
GENETICS IN MEDICINE (2020)
Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database
Stephanie Nguengang Wakap et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
Activities of daily living in myotonic dystrophy type 1
Erik Landfeldt et al.
ACTA NEUROLOGICA SCANDINAVICA (2020)
Reporting Formative Qualitative Research to Support the Development of Quantitative Preference Study Protocols and Corresponding Survey Instruments: Guidelines for Authors and Reviewers
Ilene L. Hollin et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2020)
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review
Eline van Overbeeke et al.
DRUG DISCOVERY TODAY (2019)
Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review
Vikas Soekhai et al.
DRUG DISCOVERY TODAY (2019)
Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study
Eline van Overbeeke et al.
FRONTIERS IN PHARMACOLOGY (2019)
Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs
Nigel S. Cook et al.
FRONTIERS IN MEDICINE (2019)
Caregiver Burden and Related Factors Among Caregivers of Patients with Myotonic Dystrophy Type 1
Go Kurauchi et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial
Kees Okkersen et al.
LANCET NEUROLOGY (2018)
Mitochondrial disease patient motivations and barriers to participate in clinical trials
Zarazuela Zolkipli-Cunningham et al.
PLOS ONE (2018)
EUPATI Guidance for Patient Involvement in Medicines Research and Development (R& Guidance for Pharmaceutical Industry-Led Medicines R&D
Kay Warner et al.
FRONTIERS IN MEDICINE (2018)
Review: Central nervous system involvement in mitochondrial disease
N. Z. Lax et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2017)
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research
Libby Wood et al.
JOURNAL OF NEUROLOGY (2017)
Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation-Sponsored Workshop
Sharon Hesterlee et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2017)
How Many Focus Groups Are Enough? Building an Evidence Base for Nonprobability Sample Sizes
Greg Guest et al.
FIELD METHODS (2017)
The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization
Meredith Y. Smith et al.
DRUG SAFETY (2016)
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
T. Morel et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study
Sigrid Baldanzi et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies
Martin Ho et al.
VALUE IN HEALTH (2016)
Evaluating Bang for the Buck: A Cost-Effectiveness Comparison Between Individual Interviews and Focus Groups Based on Thematic Saturation Levels
Emily Namey et al.
AMERICAN JOURNAL OF EVALUATION (2016)
Prevalence of Nuclear and Mitochondrial DNA Mutations Related to Adult Mitochondrial Disease
Grainne S. Gorman et al.
ANNALS OF NEUROLOGY (2015)
Using the framework method for the analysis of qualitative data in multi-disciplinary health research
Nicola K. Gale et al.
BMC MEDICAL RESEARCH METHODOLOGY (2013)
Quantifying Benefit-Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature
A. Brett Hauber et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2013)
Living with myotonic dystrophy; what can be learned from couples? a qualitative study
Edith H. C. Cup et al.
BMC NEUROLOGY (2011)
SURVIVAL AND CTG REPEAT EXPANSION IN ADULTS WITH MYOTONIC DYSTROPHY TYPE 1
William J. Groh et al.
MUSCLE & NERVE (2011)
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2
Y. G. Weber et al.
NEUROLOGY (2010)
Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ)
Mieke C. E. Hermans et al.
NEUROMUSCULAR DISORDERS (2010)
分享论文
